Differentiation was initiated with B2M−/−CIITA−/− rhCD47 tg hiPSC at 60% confluency, and medium was changed to RPMI-1640 containing 2% B-27 minus insulin (both Gibco) and 5 µM CHIR-99021 (Selleckchem). On day 2, the medium was changed to reduced medium: RPMI-1640 containing 2% B-27 minus insulin (Gibco) and 2 µM CHIR-99021 (Selleckchem). From days 4–7, cells were cultured in RPMI-1640 EC medium of RPMI-1640 containing 2% B-27 minus insulin plus 50 ng/ml human VEGF, 10 ng/ml human FGFb; R&D Systems), 10 µM Y-27632 (Sigma-Aldrich), and 1 µM SB 431542 (Sigma-Aldrich). Endothelial cell clusters were visible from day 7 and cells were maintained in Endothelial Cell Basal Medium 2 (PromoCell) plus 10% FCS hi (Gibco), 1% pen/strep, 25 ng/ml VEGF, 2 ng/ml FGFb, 10 µM Y-27632 (Sigma-Aldrich), and 1 µM SB 431542 (Sigma-Aldrich). The differentiation process was completed after 14 d and undifferentiated cells detached during the differentiation process. TrypLE Express (Gibco) was used for passaging the cells 1:3 every 3–4 d.
Human fgfb
Manufactured by R&D Systems
Human FGFb is a recombinant protein that belongs to the fibroblast growth factor (FGF) family. FGF family members are involved in a variety of biological processes, including cell growth, differentiation, and tissue repair. Human FGFb is a basic FGF that promotes the proliferation and migration of various cell types.
Automatically generated - may contain errors
Lab products found in correlation
B 27 minus insulin, by Thermo Fisher Scientific (2 mentions)
Y 27632, by Merck Group (2 mentions)
Fcs hi, by Thermo Fisher Scientific (2 mentions)
Tryple express, by Thermo Fisher Scientific (2 mentions)
Sb431542, by Merck Group (2 mentions)
Chir99021, by Selleck Chemicals (2 mentions)
Endothelial cell basal medium 2, by PromoCell (2 mentions)
Vascular endothelial growth factor (vegf), by Merck Group (1 mentions)
Human vegf, by R&D Systems (1 mentions)
2 protocols using human fgfb
1
Differentiation of iPSCs into Endothelial Cells
2
Endothelial Cell Differentiation from PSCs
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The differentiation protocol was initiated at 60% confluency, and medium was changed to RPMI-1640 containing 2% B-27 minus insulin (both Gibco) and 5 µM CHIR-99021 (Selleckchem). On day 2, the medium was changed to reduced medium of RPMI-1640 containing 2% B-27 minus insulin (Gibco) and 2 µM CHIR-99021 (Selleckchem). From culture days 4–7, cells were exposed to RPMI-1640 EC medium, RPMI-1640 containing 2% B-27 minus insulin plus 50 ng/ml human VEGF (R&D Systems), 10 ng/ml human FGFb (R&D Systems), 10 µM Y-27632 (Sigma-Aldrich), and 1 µM SB 431542 (Sigma-Aldrich). Endothelial cell clusters were visible from day 7, and cells were maintained in Endothelial Cell Basal Medium 2 (PromoCell) plus supplements, 10% FCS hi (Gibco), 1% pen/strep, 25 ng/ml VEGF, 2 ng/ml FGFb, 10 µM Y-27632 (Sigma-Aldrich), and 1 µM SB 431542 (Sigma-Aldrich). The differentiation protocol was completed after 14 d; undifferentiated cells detached during the differentiation process. TrypLE Express (Gibco) was used for passaging the cells 1:3 every 3–4 d.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!